Table 3.

Rank probability of tofacitinib, baricitinib, upadacitinib, filgotinib, and placebo efficacy based on the number of patients who achieved a DAS28-CRP <2.6 and DAS28-CRP ≤3.2 response

Treatment	SUCRA
DAS28-CRP <2.6
Upadacitinib 15 mg	0.985
Tofacitinib 5 mg	0.574
Baricitinib 4 mg	0.506
Filgotinib 200 mg	0.431
MTX	0.004
DAS28-CRP <3.2
Upadacitinib 15 mg	0.945
Tofacitinib 5 mg	0.699
Baricitinib 4 mg	0.469
Filgotinib 200 mg	0.387
MTX	0.001

SUCRA, surface under the cumulative ranking curve.